Angina Patients Cost Managed Care Over Twice as Much as Coronary Artery Disease Patients Without Angina
May 09 2006 - 8:00AM
PR Newswire (US)
New Pharmacoeconomic Study Also Showed ER Usage Tripled Among
Angina Patients WASHINGTON, May 9 /PRNewswire-FirstCall/ -- An
analysis of more than 165,000 patients with coronary artery disease
(CAD) enrolled in a large managed care plan from 2001-2004 showed
that the total annual healthcare cost for an angina patient was on
average more than twice as high as that of a CAD patient without an
angina diagnosis. The study was conducted by investigators from
Ingenix, a division of a large managed care organization, and CV
Therapeutics, Inc. (NASDAQ:CVTX) and was presented at the American
Heart Association's 7th Scientific Forum on Quality of Care and
Outcomes Research in Cardiovascular Disease and Stroke in
Washington, D.C. The study showed that the care of angina patients
is more costly than CAD patients without angina and that angina
patients are more likely to use the emergency department and to
have a hospital stay. According to the study, in the year following
their diagnosis, 12 percent of CAD patients without angina used the
emergency department compared to 38 percent of angina patients.
Total average annual healthcare costs for an angina patient were
around $28,000 versus approximately $12,000 for that of a CAD
patient without angina. In addition, in the year following
diagnosis the average annual direct CAD-related costs (medical and
pharmacy) for CAD patients with angina were approximately $17,000,
while those same costs for CAD patients without angina were about
$3,000. "These data clearly illustrate the substantial medical
costs and increased healthcare utilization associated with angina,"
said Mike Sweeney, M.D., vice president, medical affairs at CV
Therapeutics. Additional information regarding the American Heart
Association's 7th Scientific Forum on Quality of Care and Outcomes
Research in Cardiovascular Disease and Stroke can be accessed at
http://www.americanheart.org/. Study Details This study compared
real-world treatment patterns, cost of care and resource
utilization among 165,536 CAD patients with and without an angina
diagnosis enrolled in a large managed care plan between 2001 and
2004. Patients were considered to have a narrowly defined angina
diagnosis if they had multiple diagnoses of angina and multiple
nitrate prescriptions and were considered to have a broadly defined
angina diagnosis if they had single or multiple diagnoses of angina
and multiple prescriptions of nitrates, beta-blockers and/or
calcium channel blockers. The cost of care and resource utilization
was compared between the three groups. The complete abstract will
be published in the May 30 online edition of Circulation at
http://www.ahajournals.org/. About CV Therapeutics CV Therapeutics,
Inc., headquartered in Palo Alto, California, is a
biopharmaceutical company focused on applying molecular cardiology
to the discovery, development and commercialization of novel, small
molecule drugs for the treatment of cardiovascular diseases. CV
Therapeutics' approved products include Ranexa(TM) (ranolazine
extended-release tablets) and ACEON(R) (perindopril erbumine)
Tablets. Ranexa is indicated for the treatment of chronic angina in
patients who have not achieved an adequate response with other
antianginal drugs, and should be used in combination with
amlodipine, beta-blockers or nitrates. In addition, CV Therapeutics
co-promotes ACEON(R), an ACE inhibitor, for reduction of the risk
of cardiovascular mortality or nonfatal myocardial infarction in
patients with stable coronary artery disease and treatment of
essential hypertension. CV Therapeutics also has other clinical and
preclinical drug development candidates and programs, including
regadenoson, which is being developed for potential use as a
pharmacologic stress agent in myocardial perfusion imaging studies.
Regadenoson has not been approved for marketing by any regulatory
authorities. Except for the historical information contained
herein, the matters set forth in this press release, including
statements as to future healthcare costs and healthcare
utilization, are forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are subject to
risks and uncertainties that may cause actual results to differ
materially, including, commercialization of products; market
acceptance of products; product labeling; and other risks detailed
from time to time in CV Therapeutics' SEC reports, including its
Annual Report on Form 10-K for the year ended December 31, 2005. CV
Therapeutics disclaims any intent or obligation to update these
forward-looking statements. DATASOURCE: CV Therapeutics, Inc.
CONTACT: investors, Christopher Chai, Vice President, Treasury and
Investor Relations, +1-650-384-8560, or media, John Bluth, Senior
Director, Corporate Communications, +1-650-384-8850, both of CV
Therapeutics, Inc. Web site: http://www.cvt.com/
http://www.americanheart.org/
Copyright
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2023 to Jul 2024